Year of Award:
Molecular & Cellular Analysis Technologies
PARKER, LAURIE L.
Other PI or Project Leader:
Even with the recent development of blockbuster kinase inhibitor drugs like Gleevec, leukemias are still high on the list of deadly cancers. One reason for this is that patient response to inhibitor drugs is monitored by in- direct means (hematological re